Semaglutide Side Effects: Comprehensive Research Review

Semaglutide's safety profile, derived from >4,500 participants in the STEP weight management trials, >13,000 in the SUSTAIN diabetes trials, and >17,600 in the SELECT cardiovascular trial, demonstrates overall tolerability. The most frequent adverse events are gastrointestinal (nausea, vomiting, diarrhoea, constipation), occurring in 25–40% of treated participants. These events are predominantly mild-to-moderate, transient, and typically resolve within 4–8 weeks despite continued drug administration. Serious adverse events (acute pancreatitis, acute cholecystitis, acute kidney injury) occur at similar or lower frequencies compared to placebo controls, not suggesting causal relationships.

Real-world safety data from health systems and registries show similar adverse event profiles to trials, though discontinuation rates due to intolerance may be higher in practice settings with less intensive medical support. Post-marketing surveillance has not revealed unexpected safety signals in the approximately 5 years since approval.

Nausea is the most common gastrointestinal side effect, occurring in 25–35% of semaglutide recipients versus approximately 10% with placebo. Onset typically occurs during the dose-escalation phase (first 4–8 weeks) and peaks during the first 4 weeks of treatment. In most participants, nausea resolves within 4–8 weeks despite continued treatment ('tolerance develops'); approximately 80% of participants with initial nausea experience complete resolution. Vomiting occurs in 5–10% of treated participants and similarly shows time-dependent resolution. Diarrhoea occurs in 10–20%, and constipation in 10–15%; these are often bidirectional (some patients experience diarrhoea initially, then constipation, or vice versa), suggesting adaptation of gastrointestinal motility over time.

The mechanisms underlying these gastrointestinal effects include: (1) GLP-1 receptor activation on enteric neurons, altering gastric emptying and intestinal transit; (2) direct effects on the chemoreceptor trigger zone and vomiting centre; and (3) changes in the gut microbiota composition and metabolite production. Management strategies in clinical practice include dose escalation delays, use of anti-emetics (ginger, prescription antiemetics), dietary modifications (small frequent meals, bland diet), and reassurance regarding time-dependent resolution. Discontinuation due to gastrointestinal intolerance occurs in approximately 4–8% of trial participants but may be higher (10–15%) in real-world settings.

Acute pancreatitis has been reported with semaglutide and GLP-1 agonists generally. However, in the STEP and SUSTAIN trials, acute pancreatitis occurred at similar frequencies in semaglutide and placebo arms (approximately 0.3–0.5%), not supporting a causal relationship. Mechanistically, GLP-1 receptor agonists theoretically could increase pancreatitis risk through cholecystokinin (CCK) secretion, but clinical data do not clearly support this mechanism. Most case reports of pancreatitis with GLP-1 agonists occurred in patients with risk factors (gallstones, hypertriglyceridaemia, prior pancreatitis), confounding causality attribution.

Gallbladder-related events (biliary dyskinesia, choledocholithiasis, cholecystitis) were reported in STEP and SUSTAIN trials at similar frequencies in semaglutide and placebo arms, again not supporting a causal relationship. However, GLP-1 agonists slow gastric emptying and may alter bile flow, theoretically increasing gallstone formation. Real-world data from registries have raised concerns about increased cholecystectomy rates in GLP-1 agonist users, but causality remains uncertain. Acute kidney injury, hospitalization for heart failure, and severe infections occurred at comparable rates in semaglutide and placebo arms in trials.

Clinical guidelines recommend baseline assessment of gastrointestinal tolerability and symptoms suggestive of pancreatitis (epigastric pain) or gallbladder disease (right upper quadrant pain). Periodic monitoring of renal function is recommended, particularly in those with baseline renal disease; semaglutide is cleared hepatically with minimal renal excretion, but acute kidney injury could result from severe dehydration secondary to diarrhoea or vomiting. Monitoring of heart rate is recommended, given the modest increases (2–3 bpm) observed; however, serious arrhythmias were uncommon in trials.

Special populations require additional consideration: (1) Patients with prior pancreatitis should be counselled on pancreatitis symptoms and may warrant closer monitoring; (2) those with gallstone disease may face increased risk of biliary complications, though data are inconclusive; (3) patients with thyroid cancer history are excluded from semaglutide use due to the thyroid C-cell boxed warning; (4) renal impairment requires monitoring but does not necessarily preclude use (SUSTAIN 5 included moderate renal disease).

Long-term safety beyond 2–3 years remains incompletely characterized; most trials were of 68–104 weeks duration. Real-world post-marketing surveillance provides longer follow-up but lacks the rigorous design of randomised trials. Some emerging real-world data suggest potential increased cholecystectomy rates with GLP-1 agonists, but confounding by obesity, metabolic syndrome, and other risk factors is difficult to exclude. The long-term neurological effects of sustained GLP-1 receptor agonism (given the distributed expression in the central nervous system) are unknown.

Additionally, the thyroid C-cell tumour signal from preclinical rodent studies has not translated clinically, but the mechanism underlying species-specific toxicology remains unclear. This knowledge gap complicates risk communication to patients regarding the thyroid warning. Finally, the potential for microbiota dysbiosis from sustained semaglutide use, and any long-term immunological consequences, remain speculative areas for future research.